PMID- 38482436
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240315
IS  - 2219-6803 (Electronic)
IS  - 2218-676X (Print)
IS  - 2218-676X (Linking)
VI  - 13
IP  - 2
DP  - 2024 Feb 29
TI  - A novel gene signature related to fatty acid metabolism predicts prognosis, 
      immune landscape, and drug sensitivity in early-stage lung squamous cell 
      carcinoma.
PG  - 525-541
LID - 10.21037/tcr-23-1640 [doi]
AB  - BACKGROUND: Dysregulation of fatty acid metabolism (FAM) represents a significant 
      metabolic alteration in tumorigenesis. However, the role of FAM-related genes 
      (FAMRGs) in early-stage lung squamous cell carcinoma (LUSC) remains incompletely 
      understood. METHODS: A series of bioinformatic analyses and machine learning 
      strategies were performed to construct a FAMRGs-based signature to predict 
      prognosis and guide personalized treatment for early-stage LUSC patients. FAMRGs 
      were screened through the Kyoto Encyclopedia of Genes and Genomes (KEGG) database 
      and the Molecular Signature Database (MSigDB). Prognosis FAMRGs were identified 
      using univariate Cox regression, and unsupervised clustering analysis facilitated 
      the division of the cohort into different clusters. The least absolute shrinkage 
      and selection operator (LASSO)-Cox regression and multivariate regression 
      analysis were employed to develop a FAMRGs-based signature for predicting overall 
      survival (OS). A nomogram was subsequently constructed to facilitate risk 
      assessment for individual patients. Comprehensive analyses of metabolic pathways, 
      immune infiltration, immunomodulators, and potentially applicable drugs were 
      conducted across different FAMRGs-related risk groups. RESULTS: The FAMRGs-based 
      signature, comprising nine genes (ACOT11, APOH, BMX, CYP2R1, DPEP3, FABP6, FADS2, 
      GLYATL2, and THRSP), demonstrated robust predictive capabilities for prognosis in 
      The Cancer Genome Atlas (TCGA)-LUSC dataset and validated across six independent 
      Gene Expression Omnibus (GEO)-LUSC datasets. Notably, the FAMRGs-base signature 
      exhibited superior prognostic capacity and accurate survival prediction compared 
      to conventional clinicopathological features. Furthermore, the signature was 
      closely associated with immune cell infiltration, human leukocyte antigen (HLA) 
      genes, and immune checkpoint genes expression. Additionally, the signature 
      demonstrated potential sensitivity to chemo-/target-therapy. CONCLUSIONS: The 
      FAMRGs-based signature demonstrated superior sensitivity in predicting the 
      prognosis of early-stage LUSC. Detecting FAMRGs may provide predictive targets 
      for the development of clinical treatment strategies.
CI  - 2024 Translational Cancer Research. All rights reserved.
FAU - Xu, Juqing
AU  - Xu J
AD  - Department of Hematology and Oncology, Department of Geriatric Lung Cancer 
      Laboratory, the Affiliated Geriatric Hospital of Nanjing Medical University, 
      Nanjing, China.
AD  - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China.
FAU - Yu, Maoran
AU  - Yu M
AD  - The First School of Clinical Medicine, Nanjing Medical University, Nanjing, 
      China.
FAU - Fan, Weifei
AU  - Fan W
AD  - Department of Hematology and Oncology, Department of Geriatric Lung Cancer 
      Laboratory, the Affiliated Geriatric Hospital of Nanjing Medical University, 
      Nanjing, China.
FAU - Feng, Jifeng
AU  - Feng J
AD  - Department of Oncology, the Affiliated Cancer Hospital of Nanjing Medical 
      University, Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research, 
      Nanjing, China.
LA  - eng
PT  - Journal Article
DEP - 20240220
PL  - China
TA  - Transl Cancer Res
JT  - Translational cancer research
JID - 101585958
PMC - PMC10928631
OTO - NOTNLM
OT  - Fatty acid metabolism (FAM)
OT  - immune infiltration
OT  - lung squamous cell carcinoma (LUSC)
OT  - prognosis signature
COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure 
      form (available at 
      https://tcr.amegroups.com/article/view/10.21037/tcr-23-1640/coif). The authors 
      have no conflicts of interest to declare.
EDAT- 2024/03/14 06:47
MHDA- 2024/03/14 06:48
PMCR- 2024/02/29
CRDT- 2024/03/14 04:23
PHST- 2023/09/07 00:00 [received]
PHST- 2024/01/16 00:00 [accepted]
PHST- 2024/03/14 06:48 [medline]
PHST- 2024/03/14 06:47 [pubmed]
PHST- 2024/03/14 04:23 [entrez]
PHST- 2024/02/29 00:00 [pmc-release]
AID - tcr-13-02-525 [pii]
AID - 10.21037/tcr-23-1640 [doi]
PST - ppublish
SO  - Transl Cancer Res. 2024 Feb 29;13(2):525-541. doi: 10.21037/tcr-23-1640. Epub 
      2024 Feb 20.